ORGO Organogenesis Holdings (A)

Organogenesis Holdings Inc. to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Organogenesis Holdings Inc. to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

CANTON, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the Morgan Stanley 20th Annual Global Healthcare Conference, which is being held at the Sheraton New York Times Square Hotel in New York, NY from September 12th-14th. Management will host a fireside chat on Tuesday, September 13th at 11:45 a.m. Eastern Time.

A live audio webcast of the conference presentation will be accessible by visiting the “Upcoming Events” section on the “Investor Relations” page of Organogenesis’s website An archive of the webcast will be available for replay following the conference for approximately 30 days.

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit .



Investor Inquiries:
ICR Westwicke
Mike Piccinino, CFA
 

Press and Media Inquiries:
Organogenesis
Lori Freedman
 
EN
07/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Organogenesis Holdings (A)

 PRESS RELEASE

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Resul...

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Summary: Net revenue of $86.7 million for the first quarter of 2025, a decrease of $23.3 million compared to n...

 PRESS RELEASE

Organogenesis Supports CMS’ Local Coverage Determination Implementatio...

Organogenesis Supports CMS’ Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness Organogenesis recommends CMS also implement an integrated coverage and payment policy CANTON, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets supports the U.S. Centers for Medicare & Me...

 PRESS RELEASE

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 202...

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025 CANTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, May 8th. Management will host a conference call at 5:00 p.m. Eastern Time ...

 PRESS RELEASE

Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Resu...

Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results CANTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2024. Fourth Quarter 2024 Financial Results Summary: Net revenue of $126.7 million for the fourth quarter of 2024...

 PRESS RELEASE

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 20...

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025 CANTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2024 financial results will be reported after the market closes on Thursday, February 27th. Management will host a conference call at 5:00 p.m....

ResearchPool Subscriptions

Get the most out of your insights

Get in touch